Manifold Bio, a platform therapeutics company at the forefront of AI-driven drug discovery, has expanded its executive leadership team with the appointment of Paula Cobb as Chief Operating Officer. The announcement comes as the company accelerates its mission to develop tissue-targeted biologics through a unique integration of artificial intelligence and in vivo data generation. Cobb brings extensive operational experience to the role, joining a leadership team already strengthened by key hires earlier this year. The team includes Co-founders Gleb Kuznetsov (CEO), Pierce Ogden (CTO), and Shane Lofgren (Head of Strategy), along with Kimberly Scearce-Levie, who joined as Chief Scientific Officer. Industry veterans Steve Holtzman and Doug Williams have also joined as Executive Chair and Chair of the Strategic Advisory Board, respectively. “I’m thrilled to join Manifold Bio at a moment when the industry is just beginning to realize what it means to truly unlock the full potential of AI with translationally relevant data generation,” said Cobb. “The team has already built a powerful engine for discovering tissue-targeted protein therapeutics and secured a fantastic first deal with Roche; my focus will be on further scaling that engine into a durable, high-impact business—developing our internal pipeline, advancing partnerships, and building the operational foundation to translate this powerful platform into medicines for patients across multiple disease areas.” Manifold Bio’s proprietary platform, known as mDesign, combines AI-guided protein design with massively multiplexed in vivo testing to create highly targeted biologics. Unlike traditional discovery methods, the platform tests thousands of molecules simultaneously in living organisms, enabling the identification of effective delivery strategies and therapeutic candidates across a broad range of diseases, including neurodegenerative and metabolic conditions. “This is a first-of-its-kind engine that fuses AI-driven antibody design with the physiological relevance of in vivo data,” said Gleb Kuznetsov, Ph.D., Co-founder and CEO. “We’re expanding our leadership to drive our internal programs and build a platform with the potential to transform drug development across multiple therapeutic areas.” The addition of Cobb and other senior leaders underscores Manifold’s strategic focus on scaling its platform beyond a single disease area, leveraging its unique data and AI capabilities to create a sustainable, high-impact business. The company continues to advance its internal pipeline while expanding collaborations with global pharmaceutical partners. Manifold Bio is pioneering a new era in drug discovery by merging computational innovation with real-world biological insights, aiming to deliver transformative medicines faster and more efficiently than ever before.